TABLE 2.
Comparison of carcinogenic HPV detection results in samples collected in liquid-based medium and solid carrier devices among CVT participants by HPV HC2 and cytology resultsa
| Analysis | No. of samples |
% Positive |
Agreement |
Kappa (95% CI) | Pb | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PC+/FTA+ | PC−/FTA+ | PC+/FTA− | PC−/FTA− | Total | FTA | PC | Overall | Among positives | |||
| HPV result by HC2 | |||||||||||
| Positive | 44 | 1 | 1 | 19 | 65 | 69.2 | 69.2 | 0.97 | 0.96 | 0.93 (0.83–1.0) | 1 |
| Negative | 19 | 14 | 2 | 169 | 204 | 16.2 | 10.3 | 0.92 | 0.54 | 0.66 (0.51–0.81) | 0.004 |
| Cytology result | |||||||||||
| HSIL | 3 | 0 | 0 | 0 | 3 | 100.0 | 100.0 | 1.0 | 1.0 | — | — |
| LSIL | 20 | 1 | 2 | 13 | 36 | 58.3 | 61.1 | 0.92 | 0.87 | 0.83 (0.64–1.0) | 1 |
| Normal | 193 | 16 | 4 | 54 | 267 | 26.2 | 21.7 | 0.93 | 0.73 | 0.80 (0.71–0.88) | 0.012 |
a
The carcinogenic HPV types included HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -66, and -68/73. PC, PreservCyt, liquid-based medium; FTA, solid carrier device; HC2, HPV Hybrid Capture 2 test.
b
Calculated by using the exact McNemar χ2 test.